In this episode of In the Money with Amber Kanwar we sit down with veteran investor Gordon Reid of Goodreid Investment Counsel who is actively searching for value beyond the usual Magnificent 7 names. Reid explains how he’s managed to outperform by picking strong performers across the other 493 names in the S&P 500—and where he’s finding the most overlooked opportunities today.
Although he does hold some of the usual big tech stocks, he shares 7 stock ideas outside of the Mag 7 that he believes are positioned to outperform, spanning financials, healthcare, and industrials.
Reid offers his long-term perspective on tech concentration, American exceptionalism, and why the AI revolution is still in its early innings. In the mailbag, he weighs in on Novo Nordisk (NVO), Eli Lilly (LLY), Merck (MRK), Elevance Health (ELV), UnitedHealth (UNH), Visa (V), Uber (UBER), and RTX (RTX) — revealing which ones he’s buying, avoiding, or watching closely.
Plus: Reid’s Pro Picks are all about U.S. financials. Find out why he likes Goldman Sachs (GS), Morgan Stanley (MS), and under-the-radar Jackson Financial (JXN) — and what he sees as the next big catalyst for the sector.
